Biogenic Caralluma sinaica-derived silver nanoparticles as a synergistic antibacterial and osteoinductive nanoplatform for osteomyelitis management - Scorecard - MDSpire
Advertisement
Biogenic Caralluma sinaica-derived silver nanoparticles as a synergistic antibacterial and osteoinductive nanoplatform for osteomyelitis management
Clinical Scorecard: Silver Nanoparticles Derived from Biogenic Caralluma sinaica: A Multifunctional Approach for Antibacterial and Osteoinductive Treatment of Osteomyelitis
At a Glance
Category
Detail
Condition
Key Mechanisms
Antibacterial and osteoinductive activities through silver nanoparticles (CS-AgNPs) and plant extract.
Target Population
Care Setting
Key Highlights
CS-AgNPs/PE exhibited strong antibacterial potency against Staphylococcus aureus.
Significant reduction in bacterial burden and inflammatory response in treated mice.
Increased osteocalcin positive osteoblasts and collagen deposition in treated bone.
No cellular toxicity observed in vitro and in vivo.
CS-AgNPs/PE suppressed biofilm formation and enhanced ROS production.
Guideline-Based Recommendations
Diagnosis
Use of immune-histochemical analysis to assess infection and inflammation.
Management
Application of CS-AgNPs/PE as a treatment strategy for chronic osteomyelitis.
Monitoring & Follow-up
Assessment of bacterial burden and inflammatory markers post-treatment.
Risks
Potential for antibiotic resistance and inadequate immune response in chronic cases.
Patient & Prescribing Data
Patients with chronic osteomyelitis, particularly those resistant to conventional treatments.
CS-AgNPs/PE formulation as a dual-action therapeutic agent.
Clinical Best Practices
Consider the use of phytosynthesized nanoparticles in treatment protocols.
Monitor for signs of infection and inflammatory response during treatment.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
